Form 4: Allogene Therapeutics Executive Acquires Shares and Stock Options

Allogene Therapeutics EVP of R&D, Zachary Roberts, acquired 173,913 shares and 614,844 stock options on January 24, 2025.

Summary

• Zachary Roberts, EVP of R&D at Allogene Therapeutics, acquired 173,913 shares of common stock on January 24, 2025.
• These shares were acquired at a price of $0.
• Following this transaction, Mr. Roberts directly owns 661,967 shares of common stock.
• Mr. Roberts also acquired 614,844 stock options with an exercise price of $1.94 on the same date.
• These options vest over time, with 25% vesting on January 24, 2026, and the remainder vesting in 36 equal monthly installments thereafter.
• The stock options expire on January 24, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, but the acquisition of shares and options by an executive is generally viewed positively as it aligns their interests with shareholders.

Positives

• The acquisition of shares and stock options by a key executive could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants and share acquisitions are common forms of compensation for executives in the biotechnology and pharmaceutical industries.
• Vesting schedules, such as the one described in the document, are standard practice to incentivize long-term performance and retention.
• The specific terms of the grant, such as the exercise price and vesting schedule, are typical for executive compensation packages in similar companies.

Stakeholder Impact

• The transaction could be viewed positively by shareholders as it indicates confidence from a key executive.
• The vesting schedule of the stock options aligns the executive's interests with the long-term performance of the company.

Key Dates

Keywords

Allogene Therapeutics, stock options, share acquisition, executive, insider trading, biotechnology, pharmaceuticals, equity